Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Settle

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
British Journal of Pharmacology|September 1, 1992
Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the ratM R Wilkins, S L Settle, J E Kirk, et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|February 1, 1995
Potentiation of nitric oxide-mediated vascular relaxation by SC52608, a superoxide dismutase mimicT P Kasten, S L Settle, T P Misko, et al.
European Journal of Pharmacology|January 24, 1995
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthaseJ R Connor, P T Manning, S L Settle, et al.
The Journal of Clinical Investigation|May 1, 1997
A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivoV W Engleman, G A Nickols, F P Ross, et al.
Endocrinology|March 1, 1996
Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized ratB A Crippes, V W Engleman, S L Settle, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 1994
Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthaseT P Kasten, P Collin-Osdoby, N Patel, et al.
Cancer Research|May 15, 1998
A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancyC P Carron, D M Meyer, J A Pegg, et al.
Cancer Research|March 23, 2000
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitorsJ L Masferrer, K M Leahy, A T Koki, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
British Journal of Pharmacology|September 1, 1992
Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the ratM R Wilkins, S L Settle, J E Kirk, et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)|February 1, 1995
Potentiation of nitric oxide-mediated vascular relaxation by SC52608, a superoxide dismutase mimicT P Kasten, S L Settle, T P Misko, et al.
European Journal of Pharmacology|January 24, 1995
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthaseJ R Connor, P T Manning, S L Settle, et al.
The Journal of Clinical Investigation|May 1, 1997
A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivoV W Engleman, G A Nickols, F P Ross, et al.
Endocrinology|March 1, 1996
Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized ratB A Crippes, V W Engleman, S L Settle, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 1994
Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthaseT P Kasten, P Collin-Osdoby, N Patel, et al.
Cancer Research|May 15, 1998
A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancyC P Carron, D M Meyer, J A Pegg, et al.
Cancer Research|March 23, 2000
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitorsJ L Masferrer, K M Leahy, A T Koki, et al.
Pageof 2